CytomX Therapeutics, Inc. CTMX

CTMX Company Overview

CytomX Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing conditionally activated biologic therapeutics for oncology and, historically, immune-mediated diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on antibody-based cancer therapies designed to improve therapeutic selectivity and reduce systemic toxicity. CytomX is best known for its proprietary Probody therapeutic platform, which engineers antibodies and T-cell engaging therapies to remain largely inactive in healthy tissue and activate preferentially within the tumor microenvironment.

The company’s principal business activities center on the discovery, development, and commercialization potential of oncology therapeutics, including antibody-drug conjugates (ADCs), T-cell engagers, and immune checkpoint-directed therapies. Revenue has historically been generated primarily through collaboration agreements, licensing arrangements, research funding, and milestone payments from strategic pharmaceutical partners rather than commercial product sales. CytomX was founded in 2008 and became publicly traded in 2015. Over time, it evolved from a platform-focused biotechnology company into a more oncology-centered developer with internally advanced clinical candidates and partnered programs.